FDA Advisory Panel Endorses Pfizer’s COVID-19 Vaccine
- December 11, 2020
The New York Times (12/10, A1, Thomas, Weiland, LaFraniere) reports, “Pfizer’s COVID-19 vaccine passed a critical milestone on Thursday when a panel of experts formally recommended that the Food and Drug Administration authorize the vaccine.” The agency “is expected to grant an emergency use authorization on Saturday, according to people familiar with the agency’s planning, though they cautioned that last-minute legal or bureaucratic requirements could push the announcement to Sunday or later.”
The Hill (12/10, Weixel) reports, “The panel voted 17-4, with one abstention, that the safety and efficacy of the vaccine outweigh the risks for use in individuals age 16 and older.”
CNBC (12/10, Lovelace) reports that the agency “said Tuesday that there is currently insufficient data to make conclusions about the safety of the vaccine in children under age 16, pregnant women and people with compromised immune systems.”
NBC News (12/10, Edwards) reports that the US “would be the fourth country to move forward with Pfizer’s vaccine.”
Among other sources covering the story are the Washington Post (12/10, A1, McGinley, Johnson, Achenbach), USA Today (12/10, Weise, Weintraub), Reuters (12/10, Mishra, Steenhuysen), STAT (12/10), CNN (12/10, Fox), and the Wall Street Journal (12/10, A1, Burton, Hopkins, Subscription Publication).